GSK - Adaptimmune: Using TCRs To Fight Solid Tumors
Company Overview
Adaptimmune (ADAP) is a clinical-stage biotechnology company developing novel cell therapies in solid tumors. With their proprietary Specific Peptide Enhanced Affinity Receptor ("SPEAR") T cell platform, they identify cancer targets, find and genetically engineer T cell receptors ("TCRs") and product therapeutic candidates for administration to patients. With their affinity engineered TCRs, Adaptimmune aspires to be the first company to have a TCR T cell therapy approved for a solid tumor indication by 2022.
Technology Overview
T cells and their receptors play an important part in targeting and destroying cancer cells by